New scientifc paper: “Managing the Patient with Psoriasis and Metabolic Comorbidities”

The DocTIS team at the University of Verona, along with other researchers from the institution, has published an article in the American Journal of Clinical Dermatology discussing the relationship between psoriasis and metabolic comorbidities, such as obesity, hypertension, diabetes, dyslipidemia, and non-alcoholic fatty liver disease.

The article highlights how these conditions affect the treatment and effectiveness of medications for psoriasis. Some treatments may pose risks for patients with metabolic issues, while others may be less effective. The review also covers the mechanisms linking psoriasis with metabolic disorders and examines the safety and efficacy of both conventional and biologic drugs. Additionally, it emphasizes the importance of personalized management, including lifestyle changes like diet and physical activity, to improve outcomes for these patients.

Psoriasis is one of the six immune-mediated inflammatory diseases (IMIDs) addressed by the European DocTIS project, which aims to leverage the specificity and efficacy of modern targeted therapies.

The full open-access article can be found here: https://link.springer.com/article/10.1007/s40257-024-00857-0.